Company

Sichuan Kelun-Biotech Biopharmaceutical Co.

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 2 TRIAL

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registration with no posted results; it describes a planned neoadjuvant study in a specific population but cannot yet demonstrate efficacy or safety.

PreliminaryOsimertinib NCT07329322 Sichuan Kelun-Biotech Biopharmaceutical Co.

Reported

Planned enrollment30

PhasePhase 2

Primary outcome measureMajor Pathological Response (MPR) rate

AUG 12, 2026 · PHASE 2 TRIAL

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a registry record for an ongoing Phase 2 trial with no results posted; it describes planned enrollment and design only, not efficacy or safety outcomes.

PreliminarySKB264+SKB118 Nsclc Sichuan Kelun-Biotech Biopharmaceutical Co.

Reported

Estimated enrollment206

PhasePHASE 2

Primary outcome 1Number of Participants With Abnormal Labora…